Journal: International Journal of Nanomedicine

Article Title: Magnetic thermoablation stimuli alter BCL2 and FGF-R1 but not HSP70 expression profiles in BT474 breast tumors

doi: 10.2147/IJN.S77372

Figure Lengend Snippet: Effect of magnetic thermoablation on the BCL2, HSP70, and FGF-R1 protein expression pattern in BT474 tumors. Notes: Representative pictures after IHC staining of BCL2, HSP70, and FGF-R1 were chosen. Blue: nuclei, red: protein-specific antibody, scale bar: 100 μm. Relative semi-quantitative expression of investigated proteins is depicted in diagrams. In diagrams, bars represent the relative number of slides with a specific protein expression normalized to the total number of all slides in the specific treatment group. Bar colors represent the amount of specifically stained area within the viable tumor region: unstained/negative (light gray), less than 50% of vital area stained (dark grey), more than 50% of vital area stained (black). Whereas a downregulation of BCL2 and FGF-R1 can be assumed, HSP70 expression remained unchanged. Abbreviations: BCL2, B-cell lymphoma 2; HSP70, heat shock protein; FGF-R1, fibroblast growth factor receptor 1; IHC, immunohistochemistry; MNP, magnetic nanoparticles; AMF, alternating magnetic field.

Article Snippet: For tumor implantation, 200 μL Matrigel (BD MatrigelTM Basement Membrane Matrix; Becton Dickinson GmbH, Germany) containing 1×10 7 BT474 cells (human mammary-adenocarcinoma, Cell Lines Service, Germany) were injected subcutaneously between the shoulder blades of 6–15 week old female severe combined immune deficiency (SCID)–Balb/c mice (Harlan Laboratories, the Netherlands).

Techniques: Expressing, Immunohistochemistry, Staining

Journal: Nuclear medicine and biology

Article Title: Determining Efficacy of Breast Cancer Therapy by PET Imaging of HER2 mRNA

doi: 10.1016/j.nucmedbio.2013.08.005

Figure Lengend Snippet: DOTA-PNA-Peptide Cu-64 radiolabeling and BT474 Cellular Uptake

Article Snippet: Human BT474 BC Xenografts For tumor induction, 5–6 × 10 6 BT474 cells in 0.2 mL of culture medium, including 10 mg of Matrigel (Becton-Dickinson), were implanted intramuscularly through a sterile 27 gauge needle into the thighs of 6–8 week old female NCr immunocompromised mice (National Cancer Institute), lightly anesthetized with a mixture of ketamine (200 mg/kg), xylazine (10 mg/kg) and acetopromazine (2 mg/kg) at a dose of 160 μL/25 g, as before ( 11 ).

Techniques: Radioactivity

Journal: Nuclear medicine and biology

Article Title: Determining Efficacy of Breast Cancer Therapy by PET Imaging of HER2 mRNA

doi: 10.1016/j.nucmedbio.2013.08.005

Figure Lengend Snippet: Surface rendered F-18-FDG and Cu-64-WT4340 images of a mouse bearing BT474 tumor (arrow) in the right thigh. Images in A and C are before treatment and in B and D are after second Dox treatment. Top: Cu-64-WT4340 (A, B) Bottom: F-18-FDG (C, D). A significantly diminished uptake of Cu-64-WT4340 after Dox treatment is visible in (B) as compared to that with the F-18-FDG uptake (D). Note: significant muscle uptake of F-18-FDG in contralateral normal thigh (C).

Article Snippet: Human BT474 BC Xenografts For tumor induction, 5–6 × 10 6 BT474 cells in 0.2 mL of culture medium, including 10 mg of Matrigel (Becton-Dickinson), were implanted intramuscularly through a sterile 27 gauge needle into the thighs of 6–8 week old female NCr immunocompromised mice (National Cancer Institute), lightly anesthetized with a mixture of ketamine (200 mg/kg), xylazine (10 mg/kg) and acetopromazine (2 mg/kg) at a dose of 160 μL/25 g, as before ( 11 ).

Techniques:

Journal: Nuclear medicine and biology

Article Title: Determining Efficacy of Breast Cancer Therapy by PET Imaging of HER2 mRNA

doi: 10.1016/j.nucmedbio.2013.08.005

Figure Lengend Snippet: Percent of Pretreatment Tumor Volume (TV) and Body Weight (BW) of mice bearing BT474 Xenografts with and without (n=8) Doxorubicin Treatment (n=8)

Article Snippet: Human BT474 BC Xenografts For tumor induction, 5–6 × 10 6 BT474 cells in 0.2 mL of culture medium, including 10 mg of Matrigel (Becton-Dickinson), were implanted intramuscularly through a sterile 27 gauge needle into the thighs of 6–8 week old female NCr immunocompromised mice (National Cancer Institute), lightly anesthetized with a mixture of ketamine (200 mg/kg), xylazine (10 mg/kg) and acetopromazine (2 mg/kg) at a dose of 160 μL/25 g, as before ( 11 ).

Techniques: Control

Journal: Breast Cancer Research and Treatment

Article Title: Endosomal recycling inhibitors downregulate estrogen receptor-alpha and synergise with endocrine therapies

doi: 10.1007/s10549-023-07225-2

Figure Lengend Snippet: Endosomal recycling inhibitors downregulate ER-α and AR. A Heatmap displaying the top 30 hits from the RPPA analysis of control and 10 µM PQ-treated BT474 cells (mean of two biological replicates; * indicates AR and ER-α). B Lysates of BT474 cells treated with 10 µM PQ for 24 h were immunoblotted with the indicated antibodies. Quantitative analysis of the fold difference of hormone receptor protein levels relative to control untreated cells indicated in the histogram ( n = 3–4). MDA-MB-134 VI ( C ) and SUM44-PE ( D ) invasive lobular breast carcinoma cells were treated with the indicated concentrations of PQ for 24 h prior to lysis and immunoblotting. Histograms indicate the fold change in ER-α protein levels relative to untreated cells ( n = 4). E MCF-7 cells were treated with the indicated concentrations of PQ and MON for 24 h. Lysates were immunoblotted with ER-α and AR antibodies, and the histogram indicates the fold difference in protein levels relative to untreated cells ( n = 3)

Article Snippet: Authenticated BT474 cells were purchased from CalTag Medsystems and cultured in DMEM.

Techniques: Lysis, Western Blot